Enhanced Launches Personalized Medicine Platform, Targets $52B Peptide Market with Clinical Trials
Enhanced’s personalized performance medicine platform is now live, offering proprietary Stronger & Longer supplement blends and hormone replacement therapies for men and women as it ramps a phased product rollout. The company plans a peptide line targeting a $52 billion market, backed by IRB-approved trials on 40 elite athletes.
1. Personalized Platform Launch
Enhanced has launched its personalized performance medicine platform, debuting its proprietary Stronger & Longer supplement blends alongside hormone replacement therapies for both men and women. The phased rollout will expand product offerings designed to optimize individual health, performance, and recovery.
2. Peptide Expansion Strategy
In anticipation of FDA reclassification of 14 restricted peptides, Enhanced plans to introduce a comprehensive peptide line addressing a $52 billion global therapeutics market. The Live Enhanced platform currently offers Sermorelin and will add Tesamorelin, Glutathione, Oxytocin, and up to eight additional peptides pending regulatory approvals.
3. IRB Trial and SPAC Merger Update
Enhanced is sponsoring an IRB-approved clinical trial involving 40 elite athletes to assess the safety and tolerability of approved compounds, generating proprietary data to refine its consumer protocols and peptide formulations. Its business combination with A Paradise Acquisition Corp remains pending SEC review, positioning Enhanced for a U.S. public markets debut.